Immunotherapy and chemotherapy for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a sequence of treatments for people with a specific type of advanced colorectal cancer (called pMMR or MSS) that has not responded to earlier therapies. Patients first receive an immunotherapy combination (pembrolizumab plus a personalized dendritic cell vaccine) followed by a chemotherapy pill (trifluridine/tipiracil) plus bevacizumab. The goal is to see if this sequence can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer that has spread to other parts of the body (metastatic) and is a type called pMMR or MSS.
- You have received 1 to 2 prior chemotherapy treatments for advanced disease, which included drugs like fluoropyrimidines, irinotecan, oxaliplatin, and possibly a targeted therapy.
- You are healthy enough to undergo leukapheresis (a procedure to collect white blood cells) and have normal blood, kidney, and liver function.
- You have not had prior treatment with trifluridine/tipiracil (FTD/TPI) for your colorectal cancer.
- You do not have an active autoimmune disease or a condition that requires steroid treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of oral chemotherapy, targeted therapy, and immunotherapy, with or without radiation, for people with advanced colorectal cancer that hasn't responded to at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow the disease.
This trial tests whether adding the immunotherapy drug adebrelimab to standard chemotherapy plus bevacizumab can help people with a specific type of metastatic colorectal cancer that cannot be removed by surgery. It is for patients whose tumors are microsatellite stable (MSS) or have normal mismatch repair (pMMR).
This trial tests a personalized vaccine made from your own tumor cells for advanced colorectal cancer that is mismatch repair proficient (pMMR). It aims to see if the vaccine can help when standard treatments have stopped working.
This trial tests a personalized vaccine made from your tumor's unique features, combined with a standard second-line treatment, for colorectal cancer that has worsened after the first treatment. The goal is to see if this combination can help control the cancer better than standard therapy alone.
This trial tests a new combination of ultra-precise radiation therapy, immunotherapy, chemotherapy, and targeted therapy for people with metastatic colorectal cancer that has a normal DNA mismatch repair system. The goal is to see if this personalized approach can better control the cancer and improve outcomes.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
Hear when a new Microsatellite Stable Colorectal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.